Sort
53,477 grants matching “addiction”
Microdialysis Studies of Self-administrationx
$2,947,429Roy A Wise · National Institute On Drug Abuse · ZIA · FY2009 · DA
Neuronal networks for control of eye movement
$2,944,856Okihide Hikosaka · National Eye Institute · ZIA · FY2025 · EY
fMRI Study of Motivation, Decision-Making, Reward, Risk, Aversion, Craving, impulsivity, and Stress in Alcohol Use Disorders
$2,943,229Abdolreza Momenan · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2016 · AA
JCOIN Phase II Coordination and Translation Center
$2,941,811Faye S Taxman · George Mason University · U2C · FY2025 · DA
Validation of blocking TSP4/Cava2d1 interaction as a new target for neuropathic pain
$2,940,765Zhigang David Luo · University Of California-Irvine · R01 · FY2019 · DE
Lead Optimization and Preclinical Development of Human Nicotine-Specific mAbs
$2,939,717Matthew W Kalnik · Antidote Therapeutics, Inc. · R01 · FY2016 · DA
Growth factors, neuroinflammation, exercise, and brain integrity
$2,938,975Paul M Thompson · University Of Southern California · RF1 · FY2014 · AG
Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders
$2,937,963John Cureton Hunter · Siteone Therapeutics, Inc. · UG3 · FY2019 · DA
Center for Adolescent Reward, Rhythms and Sleep (CARRS)
$2,937,638Colleen A McClung · University Of Pittsburgh At Pittsburgh · P50 · FY2021 · DA
TREATMENT OF ADDICTIONS--BIOLOGICAL CORRELATES
$2,936,379Rockefeller University · P60 · FY2004 · DA
Center for Adolescent Reward, Rhythms and Sleep (CARRS)
$2,936,360Colleen A McClung · University Of Pittsburgh At Pittsburgh · P50 · FY2020 · DA
Microdialysis Studies of Self-administrationx
$2,932,169Roy A Wise · National Institute On Drug Abuse · Z01 · FY2007 · DA
JCOIN Coordination and Translation Center
$2,930,787Faye S Taxman · George Mason University · U2C · FY2020 · DA
Optimization and Development of Non-Hallucinogenic 5-HT2A/2C Agonists as Opioid Use Disorder Therapeutics
$2,923,842Glenn Short III · Atai Therapeutics, Inc. · UG3 · FY2025 · DA
Novel Medication Approaches for Substance Abuse
$2,920,862Herbert David Kleber · New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc · P50 · FY2006 · DA
Development of ITI-333, a μ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders
$2,917,074Gretchen L Snyder · Intra-Cellular Therapies, Inc. · UG3 · FY2021 · DA
Registration Development Program for LUCEMYRA (Lofexidine) Label Expansion for Opioid Withdrawal Treatment in Adolescents
$2,916,742Lee Schmidt · Uswm, Llc · UG3 · FY2024 · DA
Adapting the HOPE Online Support Intervention to Increase MAT Uptake Among OUD Patients
$2,912,721Sean Young · University Of California-Irvine · R33 · FY2020 · AT
TREATMENT OF ADDICTIONS-BIOLOGICAL CORRELATES
$2,912,467Mary J Kreek · Rockefeller University · P60 · FY2008 · DA
Validation of Fibroblast-Derived PI16 as a Novel Target for pain Treatment
$2,908,421Andrew John Shepherd · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · NS
Allosteric Targeting of Cannabinoid CB1 Receptor to Develop Non-Addictive Small Molecule Analgesics
$2,903,097Dai Lu · Texas A&M University Health Science Ctr · UG3 · FY2022 · NS
Multimodal preclinical imaging studies of decisional determinants of drug vs non-drug choice
$2,901,576Charles Bradberry · National Institute On Drug Abuse · ZIA · FY2022 · DA
5/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium
$2,893,045Weili Lin · Univ Of North Carolina Chapel Hill · U01 · FY2025 · DA
Brain Imaging of Human Drug Abuse
$2,892,727Elliot A Stein · National Institute On Drug Abuse · Z01 · FY2008 · DA
Transition from Acute to Chronic Pain in Total Knee Arthroplasty Patients: Identifying Resilience and Vulnerability Profiles
$2,891,192John W. Burns · Rush University Medical Center · UM1 · FY2021 · NS